Inhalation

INH1026

Issue link: https://www.e-digitaleditions.com/i/1546950

Contents of this Issue

Navigation

Page 33 of 43

32 OctOber 2026 Inhalation of Aerosol Medicine and Pulmonary Drug Delivery 2015, 28, 353-360, doi:10.1089/jamp.2014.1172. 29. Astudillo, A.; Leung, S.S.Y.; Kutter, E.; et al. Nebulization Effects on Structural Stability of Bac- teriophage PEV 44. European Journal of Pharma- ceutics and Biopharmaceutics 2018, 125, 124-130, doi:10.1016/j.ejpb.2018.01.010. 30. Porat, S.B.; Gelman, D.; Yerushalmy, O.; et al. Expanding Clinical Phage Microbiology: Simulat- ing Phage Inhalation for Respiratory Tract Infec- tions. ERJ Open Research 2021, 7, doi:10.1183/ 23120541.00367-2021. 31. Turgeon, N.; Toulouse, M.-J.; Martel, B.; et al. Comparison of Five Bacteriophages as Models for Viral Aerosol Studies. Applied and Environmental Microbiology 2014, 80, 4242-4250, doi:10.1128/ AEM.00767-14. 32. Sawant, S.S.; Patil, S.M.; Shukla, S.K.; et al. Pulmonary Delivery of Osimertinib Liposomes for Non-Small Cell Lung Cancer Treatment: Formu- lation Development and In Vitro Evaluation. Drug Delivery and Translational Research. 2022, 12, 2474-2487, doi:10.1007/s13346-021-01088-0. 33. Daram, A.; Sawant, S.S.; Mehta, D.A.; et al. Inhalable Anti-EGFR Antibody-Conjugated Osim- ertinib Liposomes for Non-Small Cell Lung Can- cer. Pharmaceutics 2024, 16, 1444, doi:10.3390/ pharmaceutics16111444. 34. Chauhan, G.; Shaik, A.A.; Sawant, S.S.; et al. Continuously Producible Aztreonam-Loaded Inhalable Lipid Nanoparticles for Cystic Fibro- sis-Associated Pseudomonas Aeruginosa Infections – Development and In-Vitro Characterization. Bioma- terials Advances 2025, 166, 214027, doi:10.1016/j. bioadv.2024.214027. 35. Cipolla, D.; Gonda, I.; Chan, H.-K. Liposomal Formulations for Inhalation. erapeutic Delivery 2013, 4, 1047-1072, doi:10.4155/tde.13.71. 36. Sawant, S.S.; Ahmed, M.U.; Gantala, N.-G.; et al. Development of Inhalable Bacteriophage Liposomes Against Pseudomonas Aeruginosa. Pharmaceutics 2025, 17, 405, doi:10.3390/pharmaceutics17040405. 37. Cinquerrui, S.; Mancuso, F.; Vladisavljević, G.T.; et al. Nanoencapsulation of Bacteriophages in Lipo- somes Prepared Using Microfluidic Hydrodynamic Flow Focusing. Frontiers in Microbiology 2018, 9, 2172, doi:10.3389/fmicb.2018.02172. 38. Leung, S.S.; Morales, S.; Britton, W.; et al. Microfluidic-Assisted Bacteriophage Encapsula- tion into Liposomes. International Journal of Phar- maceutics 2018, 545, 176-182, doi:10.1016/j. ijpharm.2018.04.063. 39. Li, J.; Zheng, H.; Leung, S.S.Y. Investigating the Effectiveness of Liposome-Bacteriophage Nanocom- plex in Killing Staphylococcus Aureus Using Epithe- lial Cell Coculture Models. International Journal of 17. Longest, W.; Spence, B.; Hindle, M. Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2019, 32, 317-339, doi:10.1089/jamp.2018.1508. 18. Weers, J.G.; Miller, D.P. Formulation Design of Dry Powders for Inhalation. Journal of Pharmaceu- tical Sciences 2015, 104, 3259-3288, doi:10.1002/ jps.24574. 19. Encinas, D.; Martinez-Flores, P.; García, J.; et al. Latest Advances in Inhalable Dry Powder Bacteriophage erapy for Pulmonary Infections. Pharmaceutics 2025, 17, 1077, doi:10.3390/ pharmaceutics17081077. 20. Barr, J.J.; Auro, R.; Furlan, M.; et al. Bacteriophage Adhering to Mucus Provide a Non-Host- Derived Immunity. Proceedings of the National Academy of Sciences 2013, 110, 10771-10776, doi:10.1073/ pnas.1305923110. 21. Ling, K.-M.; Stick, S.M.; Kicic, A. Pulmonary Bac- teriophage and Cystic Fibrosis Airway Mucus: Friends or Foes? Frontiers in Medicine (Lausanne) 2023, 10, 1088494, doi:10.3389/fmed.2023.1088494. 22. Bichet, M.C.; Adderley, J.; Avellaneda-Franco, L.; et al. Mammalian Cells Internalize Bacterio- phages and Use em as a Resource to Enhance Cel- lular Growth and Survival. PLOS Biology 2023, 21, e3002341, doi:10.1371/journal.pbio.3002341. 23. Zamora, P.F.; Reidy, T.G.; Armbruster, C.R.; et al. Lytic Bacteriophages Interact with Respira- tory Epithelial Cells and Induce the Secretion of Antiviral and Proinflammatory Cytokines. bioRxiv 2024, 2024.02.06.579115, doi:10.1101/2024.02 .06.579115. 24. Abedon, S.T. Phage erapy of Pulmonary Infec- tions. Bacteriophage 2015, 5, e1020260, doi:10.108 0/21597081.2015.1020260. 25. Sharma, R.; Mahadevan, R.; Divyash, S.; et al. Pharmacokinetics and Physiologically Based Phar- macokinetic Modeling of Mycobacteriophages: Insights into Pulmonary Distribution and Clearance. bioRxiv 2026, 2026.01.27.702067, doi:10.64898/ 2026.01.27.702067. 26. Tovkach, F.I.; Zhuminska, G.I.; Kushkina, A.I. Long-Term Preservation of Unstable Bacteriophages of Enterobacteria. Microbiological Journal 2012, 74, 60-66. 27. Carrigy, N.B.; Chang, R.Y.; Leung, S.S.Y.; et al. Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler. Pharmaceutical Research 2017, 34, 2084-2096, doi:10.1007/s11095-017-2213-4. 28. Sahota, J.S.; Smith, C.M.; Radhakrishnan, P.; et al. Bacteriophage Delivery by Nebulization and Efficacy Against Phenotypically Diverse Pseudomo- nas Aeruginosa from Cystic Fibrosis Patients. Journal

Articles in this issue

view archives of Inhalation - INH1026